Literature DB >> 1583332

Association of biologic false-positive reactions for syphilis with human immunodeficiency virus infection.

A M Rompalo1, R O Cannon, T C Quinn, E W Hook.   

Abstract

The prevalence of biologic false-positive (BFP) reactions for syphilis (reactive rapid plasma reagin [RPR] test, nonreactive fluorescent treponemal antibody absorption [FTA-ABS] test) among patients attending two sexually transmitted disease (STD) clinics was evaluated to assess relationships between BFP reactions and human immunodeficiency virus (HIV) infection. Among 4863 patients, 357 (7.3%) had serologic evidence of syphilis and 4.9% had HIV infection. Only 40 patients (0.8% of total patients, 11% of those with reactive RPR tests) had BFP serologic tests for syphilis. There were no demographic differences between true syphilis and BFP patients as to sex, age, or intravenous drug use. BFP patients tended to have lower RPR titers (less than or equal to 1:4) than did true syphilis patients. After excluding 317 patients with reactive FTA-ABS tests, BFP RPR tests were seen in 6 (4%) of 159 HIV-seropositive patients and 34 (0.8%) of 4387 HIV-seronegative patients (odds ratio, 5.0; 95% confidence interval, 1.9-12.7). Although more common among HIV-infected than HIV-uninfected patients, BFP reactions are relatively rare among STD clinic patients, and 89% of patients with reactive RPR or VDRL serologic tests for syphilis had current or prior syphilis infection. The RPR test remains useful for guiding decisions regarding therapy for syphilis.

Entities:  

Mesh:

Year:  1992        PMID: 1583332     DOI: 10.1093/infdis/165.6.1124

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

Review 1.  Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features.

Authors:  A E Singh; B Romanowski
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

2.  Performance of routine syphilis serology in the Ethiopian cohort on HIV/AIDS.

Authors:  J W Dorigo-Zetsma; D Belewu; H Meless; E Sanders; R A Coutinho; A Schaap; D Wolday
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

3.  Hepatitis C virus infection and biological false-positive syphilis tests.

Authors:  M Augenbraun; A French; M Glesby; L Sanchez-Keeland; M Young; R Greenblatt; A Sharma
Journal:  Sex Transm Infect       Date:  2010-04       Impact factor: 3.519

Review 4.  Syphilis in adults.

Authors:  B T Goh
Journal:  Sex Transm Infect       Date:  2005-12       Impact factor: 3.519

5.  Challenging cases in HIV medicine from Bellevue Hospital: HIV and syphilis--diagnostic and therapeutic approach.

Authors:  Giraldina Trevejo-Nunez; Demetre C Daskalakis
Journal:  MedGenMed       Date:  2007-05-23

6.  Nontreponemal tests in the diagnosis of neurosyphilis: an evaluation of the Venereal Disease Research Laboratory (VDRL) and the Rapid Plasma Reagin (RPR) tests.

Authors:  Rita Castro; Emília Simões Prieto; Filomena da Luz Martins Pereira
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

Review 7.  The endemic treponematoses.

Authors:  Lorenzo Giacani; Sheila A Lukehart
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

8.  [Syphilis. Part 2: Laboratory diagnostics, therapy and prevention].

Authors:  G Gross; B Flaig; S Rode
Journal:  Hautarzt       Date:  2013-11       Impact factor: 0.751

9.  Frequency and Characteristics of Biological False-Positive Test Results for Syphilis Reported in Florida and New York City, USA, 2013 to 2017.

Authors:  James Matthias; Ellen J Klingler; Julia A Schillinger; Gayle Keller; Craig Wilson; Thomas A Peterman
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

10.  Serologic screening for herpes simplex virus type 2 in persons with human immunodeficiency virus.

Authors:  Nicholas J Van Wagoner; Rhoda Morrow; Jeannette Lee; Paula Dixon; Edward W Hook
Journal:  Am J Med Sci       Date:  2013-08       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.